



ISPOR 7TH ASIA-PACIFIC CONFERENCE

**3-6 SEPTEMBER 2016
SUNTEC CONVENTION &
EXHIBITION CENTER
SINGAPORE**

CALL FOR ABSTRACTS

Abstract Submission Opens: Monday, 16 November 2015
Abstract Submission Deadline: Thursday, 17 March 2016
Early Registration Deadline: Tuesday, 19 July 2016



*Pharmacoeconomics and Outcomes Research
in Asia-Pacific: Challenges, Opportunities,
and Future Direction*

CO-ORGANIZED BY

ISPOR Asia Consortium
ISPOR Singapore Chapter • ISPOR Malaysia Chapter • ISPOR Indonesia Chapter

CONFERENCE PROGRAM CO-CHAIRS

Wai Keung Chui, PhD, Associate Professor & Head, Department of Pharmacy, National University of Singapore, Singapore

Syed Aljunid, MD, PhD, Professor, Health Economics & Public Health Medicine, and Head, International Centre for Casemix and Clinical Coding, Faculty of Medicine, National University of Malaysia, Kuala Lumpur, Malaysia

Ahmad Fuad Afdhal, PhD, Director, Center for Socio-Economic Studies in Pharmacy, Jakarta, Indonesia

CONFERENCE PROGRAM COMMITTEE

RESEARCH REVIEW COMMITTEE CO-CHAIRS

Kenneth KC Lee, JP, MPhil, PhD Reg Pharm (HK), Professor of Pharmacy & Head, School of Pharmacy, Monash University, Selangor, Malaysia
Takashi Fukuda, PhD, Director, Department of Health and Welfare Services, National Institute of Public Health, Saitama, Japan
Xin Sun, PhD, Professor, Chinese Evidence-Based Medicine Center, West China Hospital, Sichuan University, Chengdu, Mainland China
Chee-Jen Chang, PhD, Director, Clinical Informatics and Medical Statistics Research Center, and Professor, Graduate Institute of Clinical Medical Sciences, Chang Gung University, TaoYuan, Taiwan

ISSUE PANEL REVIEW COMMITTEE CO-CHAIRS

Suresh K. Gupta, PhD, Professor Emeritus & Head, Clinical Research, Delhi Institute of Pharmaceutical Sciences & Research, University of Delhi, New Delhi, India
Peng Dong, MD, PhD, Associate Director, HEOR, Pfizer, Beijing, Mainland China

WORKSHOP REVIEW COMMITTEE CO-CHAIRS

Vithaya Kulsomboon, PhD, Associate Professor & Associate Dean, Social Pharmacy Department, Chulalongkorn University, Bangkok, Thailand
SeungJin Bae, PhD, Assistant Professor, Ewha Women's University, College of Pharmacy, Seoul, South Korea

SUPPORTING INSTITUTIONS

- Aga Khan University (Pakistan)
- Center for Socio-Economic Studies in Pharmacy (Indonesia)
- China Center for Health Economic Research of Peking University (CCHER)
- China Society for Pharmacoeconomics and Outcomes Research (CSPOR)
- Chinese University of Hong Kong School of Pharmacy (China)
- Fudan University Center for Pharmacoeconomic Research and Evaluation (China)
- Gulf Medical University (UAE)
- Institute of Health Management Research University (India)
- International University of Health and Welfare (Japan)
- Jaipur College of Pharmacy (India)
- Jinan University Pharmaceutical Economics and Health Technology Assessment Research Center (China)
- Kazakh Agency for Health Technology Assessment (Kazakhstan)
- Manipal University College of Pharmaceutical Sciences (India)

- Monash University Malaysia School of Pharmacy (Malaysia)
- National University of Singapore Saw Swee Hock School of Public Health
- Nirmala College of Pharmacy (India)
- Raghavendra Institute of Pharmaceutical Education & Research (India)
- Seoul National University Institute of Health and Environment (South Korea)
- Singapore Exhibition & Convention Bureau (SECB), A Group of Singapore Tourism Board (STB)
- Shenyang Pharmaceutical University (China)
- St Peter's Institute of Pharmaceutical Sciences (India)
- Taiwan Society for Pharmacoeconomics and Outcomes Research
- University of Delhi Delhi Institute of Pharmaceutical Sciences and Research (India)
- University of Medicine and Pharmacy (Viet Nam)
- ISPOR Regional Chapters in China, India, Indonesia, Mongolia, New Zealand, South Korea, and the Philippines

ISPOR 7TH ASIA-PACIFIC CONFERENCE

SHORT COURSES

SATURDAY 3 SEPTEMBER
MORNING COURSES (8:00AM-12:00PM)**Introduction to Pharmacoeconomics/Health Economics**

This course will include the basic theory for determining cost and outcomes, the different types of costs and costing methods, including cost minimization, cost-benefit analysis, cost-utility (cost per QALY), cost-effectiveness, and incremental cost effectiveness ratios (ICERS).

Introduction to Modeling

This course will introduce pharmacoeconomic modeling techniques such as decision analytic modeling, Markov modeling, discrete event models, and other modeling techniques and their appropriate usages with practical application, along with a review of the *ISPOR Modeling Good Research Practices*.

New! Health Care Data and Informatics in Asia

This course will discuss issues surrounding health care data in Asia, including data collection and sharing, data management, and data utilization (analytics), as well as issues of transferability, variability and other challenges. Emerging trends in big data and their future role in Asia will also be introduced.

Elements of Pharmaceutical/Biotech Pricing I - Introduction

This course will give participants a basic understanding of the key terminology and issues involved in pricing decisions and the principles of reimbursement methodologies. Tools to document product value, the role of pharmacoeconomics, and the differences in payment systems that help pricing decisions will be presented.

Introduction to Health Technology Assessment

This course will cover key principles, elements, methods, and language of health technology assessment (HTA) and provide an overview of basic HTA disciplines, including benefit assessment (biostatistics, clinical epidemiology, patient-relevant outcomes, risk-benefit assessment), economic evaluation (costing, cost-effectiveness analysis, pharmacoeconomic modeling, budget impact analysis, resource allocation), and ELSI (ethical, legal and social implications).

Cost-Effectiveness Analysis Alongside Clinical Trials

This course will present the design, conduct and reporting of cost-effectiveness analyses alongside clinical trials, referring to the *ISPOR Good Research Practices on CEA alongside Clinical Trials*. Trial design, selecting data elements (measures of cost and outcomes), database design and management, and analysis and reporting of results will be presented.

SATURDAY 3 SEPTEMBER
AFTERNOON COURSES (1:00PM-5:00PM)**Modeling: Design and Structure of a Model**

This course will provide a hands-on approach to pharmacoeconomic modeling techniques as outlined in the *ISPOR Principles of Good Practice for Decision Analytic Modeling in Health Care Evaluations*. The steps involved with model structure, data inputs (data identification, data modeling, and data incorporation) and data validation (internal, between-models, external, and prediction) will be discussed.

Patient-Reported Outcomes Measures (PROMs): Cross-Cultural Development and Validation

This course will introduce the definitions and concepts, methodologies and practical methods for measuring patient-reported outcomes, along with strategy for appropriate instrument selection and validation with considerations for regional needs. *The ISPOR Principles of Good Practice for the Translation and Cultural Adaptation Process for Patient-Reported Outcomes (PRO) Measures* will be reviewed.

Retrospective Database Design and Analysis

This course will cover fundamental design strategies, analytical techniques and specific best practices to improve causal inference in studies using retrospective databases. Specific topics include: measurement of exposure and outcome, measures of comorbidity, Cox proportional hazards survival analysis, propensity scoring, and marginal structural models.

Meta-Analysis and Systematic Literature Review in Comparative Effectiveness Research

This course highlights and expounds upon six key areas: 1) comparative effectiveness research; 2) impetus for meta-analysis and systematic reviews; 3) basic steps to perform a quantitative systematic review; 4) statistical methods of combining data; 5) reporting of results; and 6) appraisal and use of meta analytic reports.

New! Case Studies in Pharmaceutical/Biotech Pricing II – Advanced

Case studies will be employed to lead participants through the key steps of new product pricing, with focus on the need to thoroughly analyze the business environment and its constraints and opportunities, and the need to closely integrate the pricing, reimbursement, and pharmacoeconomic strategy for the new product with the clinical development and marketing strategies.

Case Studies in Health Technology Assessment

This course will provide a hands-on approach to health technology assessment (HTA), teaching participants how to apply HTA disciplines in conducting assessments, generate recommendation reports and communicate their findings effectively to health care decision makers. Case studies from countries in Asia will be examined, including impact of new policy interventions.

SUNDAY 4 SEPTEMBER
MORNING COURSES (8:00AM-12:00PM)**Statistical Considerations in Health Economic Evaluations**

This course will discuss statistical considerations when dealing with patient-level cost data, including the effect of distributional assumptions, univariate and multivariable analyses of data, sample size and power calculations, and estimation of sampling uncertainty for cost-effective analysis. Examples will be provided to illustrate concepts.

Health-Related Quality of Life (HRQOL) Weights for Economic Evaluations

This course covers Health-Related Quality of Life (HRQOL) Measures to support economic evaluations. Standard gamble, time trade-off and rating scales will be introduced, along with a presentation of the different generic instruments such as the EQ-5D, Health Utilities Index and SF-36.

Network Meta-Analysis and Indirect Treatment Comparisons

This course will cover the concepts and assumptions of network meta-analysis (indirect and mixed treatment comparisons), such as heterogeneity, transitivity, and consistency to critically analyze the results of network meta-analysis, referring to the *ISPOR Good Research Practices for Conducting and Interpreting Network Meta-Analysis and Indirect Treatment Comparisons*.

Budget Impact and Cost Analysis

This course will describe methods to determine the costs associated with a health condition and the budget impact of new technologies. Static and dynamic budget impact models and how to design a study to estimate the budget impact of a new health care intervention will be introduced, along with the *ISPOR Good Research Practice Guidance on Budget Impact Analysis*.

Risk-Sharing/Performance-Based Schemes for Drugs & Medical Devices

This course will introduce risk-sharing / performance-based arrangements between payers and producers of health technology. Although these arrangements are growing in appeal, there can be barriers to their implementation. Theory and practice, including incentives and barriers, will be analyzed along with several country-specific examples.

New! Health Care Systems in Asia

This course will introduce key components of health care systems including health care costs, quality and access. It will focus on major characteristics of health care systems in Asia including health care needs and spending, management of essential medical products and technology, health financing systems, health care governance, access to health services, and outcome measurements through the use of multi-country case studies.

**3 New Courses Featured in 18 Short Course Program!
Over 1,000 Short Course Registrants at the ISPOR
6th Asia-Pacific Conference, Beijing, China in 2014!**

ISPOR 7TH ASIA-PACIFIC CONFERENCE

CALL FOR ABSTRACTS

Abstract Submission Opens: Monday, 16 November 2015 / Abstract Submission Deadline: Thursday, 17 March 2016

SUBMISSION INSTRUCTIONS

All abstracts and proposals MUST be submitted through ISPOR's online abstract submission system by 17 March 2016.

Abstracts accepted for other ISPOR meetings cannot be submitted. A research abstract, that was submitted to another meeting and copyright transferred, is not allowed.

SUBMISSION INSTRUCTIONS, EXAMPLES & SPECIFIC EVALUATION CRITERIA AVAILABLE AT www.ispor.org

RESEARCH ABSTRACTS

Outcomes research on all health care interventions (including drugs, devices, behavioral modification programs, surgery, disease prevention, gene therapy, screening, diagnostic procedures, and health education) and on all diseases or health disorders are considered. Research abstracts (except for conceptual papers) must be organized by OBJECTIVES, METHODS, RESULTS, CONCLUSIONS. All accepted research abstracts are published in *Value in Health* as submitted. Accepted research is presented as a 15 minute podium presentation or poster presentation (with a poster author discussion hour). Abstracts are evaluated on the quality of the study (or concept) and quality of the abstract presentation. Research topics include: **Clinical Outcomes Studies, Cost Studies, Patient-Reported Outcomes & Patient Preference Research Issues, Health Care Use & Policy Studies, Research on Methods, and Conceptual Papers.** See the ISPOR website for research subtopics, diseases, and health care treatments.

ISSUE PANEL PROPOSALS

Issue panel proposals should demonstrate real debate on new or controversial issues in health economics and outcomes research or real debate on the use of outcomes research in health care decision making. Issue panel proposals must be organized MODERATOR, PANELISTS, ISSUE, OVERVIEW. Accepted issue panels are one hour in duration with a moderator and 2-3 panelists representing different organizations. Panelists should present distinct views about the topic. Issue Panel topics are: **Clinical Outcomes Research Issues, Economic Outcomes Research Issues, Patient-Reported Outcomes & Patient Preference Research Issues, Health Policy Development Using Outcomes Research Issues.** See the ISPOR website for issue panel subtopics.

WORKSHOP PROPOSALS

Workshop proposals should demonstrate novel and innovative experiences in the conduct of outcomes research (including, but not limited to, experiences with conjoint analysis, large database analysis, modeling, observational studies, record review, surveys, sensitivity analysis, and patient registries) or novel and innovative experiences in the use of outcomes research (clinical, economic, or patient-reported & patient preference outcomes) in health care policy development. Workshop proposals must be organized by DISCUSSION LEADERS, PURPOSE, DESCRIPTION. Accepted workshops are one hour in duration with a minimum of 2 and maximum of 4 discussion leaders (more than one organization must be represented). An audience interactive element must be included in the proposal and during the workshop. Workshop topics include: **Clinical Outcomes Research, Economic Outcomes Research, Patient-Reported Outcomes & Patient Preference Research, Use of Real World Data, Health Policy Development Using Outcomes Research.** See the ISPOR website for workshop subtopics.

WHY SUBMIT TO ISPOR?

ISPOR is recognized globally as the leading educational and scientific organization for outcomes research and its use in health care decisions. The Asia-Pacific Conference is the place to share your new research as a podium or poster presentation, interact with attendees during a workshop on your innovative experiences in outcomes research, or debate your views on a controversial topic in an issue panel session.

Audience: Over 1,200 attendees from the global HEOR community – researchers, regulators, decision makers, and global leaders

Advance the Science: Contribute your research, ideas, and knowledge

Research Impact: The attendee profile, ISPOR's global recognition, and the promotion and dissemination of meeting content improves the impact of your research

Career Development: Be part of this international network, become eligible for presentation awards, and be cited in *Value in Health* (all accepted research included)

Recognition: Excellent posters and research proposals will be eligible for being selected for prestigious Best Research Podium Presentations and Best Research Poster Presentations awards

PRELIMINARY PROGRAM

First Plenary: Health Technology Assessment (HTA) and Health Policy: Recent Developments across Asia

Health systems in Asia are undergoing a period of rapid change as they struggle to cope with immediate challenges such as expanding elderly populations, growing demand for high-quality health care and the need to address inequitable access to health care. In light of these issues, health technology assessment (HTA) will be essential as a means to inform evidence-based decisions and ensure efficient use of scarce resources. This session will provide insight into the current status of HTA and related health policy in Asia, sharing perspectives and experiences, lessons learned, and future trends.

Second Plenary: Harnessing the Power of Big Data to Make Better Health Care Decisions in the Asia-Pacific Region

Health care in Asia is embracing the global big data movement since big data has tremendous potential to add value in all health care settings. This session will discuss key ways how big data can deliver value through clinical and financial benefits to health systems such as aiding personalized medicine and streamlining health resource planning. It will also discuss current challenges and opportunities for utilizing big data to improve health care decision making in the Asia-Pacific region while addressing multi-stakeholder perspectives and regional considerations.

Third Plenary: Universal Health Care - the Affordable Dream in ASEAN: Experiences and Lessons Learned

The vast diversity in the historical, socio-economic, cultural and political spheres has contributed to highly divergent health statuses and health systems across countries of the Association of Southeast Asian Nations (ASEAN). With increasing educational levels and affluence, ageing populations, availability of new health technology and growing consciousness of human rights in this region, the demand for universal health coverage (UHC) of affordable and good quality health services is increasing. While a few countries in ASEAN like Singapore and Thailand have already achieved UHC, others are moving towards it. This session will discuss the current situation, challenges and opportunities for UHC in ASEAN, with the aim of sharing experiences and supporting each other in the joint pursuit of UHC.

- Over 1200 attendees expected!
- 40 Research Podium Presentations
- 30 Issue Panels & Workshops
- 5 Asia Consortium Forums
- Over 600 Research Poster Presentations

ISPOR 7TH ASIA-PACIFIC CONFERENCE

REGISTRATION FEES (Early Registration Deadline: 19 July 2016)

Regular	US\$125 (SGD 175)	US\$200 (SGD 245)
Full-Time Student	US\$75 (SGD 105)	US\$100 (SGD 140)
Full Time Host Country Student*	US\$50 (SGD 70)	US\$75 (SGD 105)
CONFERENCE REGISTRATION	THRU 19 JULY 2016	AFTER 19 JULY 2016
Standard	US\$650 (SGD 909)	US\$750 (SGD 1,048)
Full Time Government, Academia and Practitioners	US\$350 (SGD 489)	US\$450 (SGD 629)
Full Time Host Country Government, Academia and Practitioners*	US\$275 (SGD 384)	US\$375 (SGD 524)
Full Time Student	US\$125 (SGD 175)	US\$175 (SGD 245)
Full Time Host Country Student*	US\$75 (SGD 105)	US\$125 (SGD 175)

*Host Country: Individuals residing in Singapore, Malaysia or Indonesia
 Note: The SGD prices should be used as a reference and are based on currency exchange rate as of October 23, 2015.

CONFERENCE SUPPORT OPPORTUNITIES

ISPOR offers unique opportunities to increase visibility and exposure throughout the region through conference sponsorships

Event Sponsorship

Increase your visibility!

Give your company increased prominence as an event sponsor. For more information, please e-mail: eventsponsor@ispor.org

Sponsors from the 2014 Conference included:

Bristol-Myers Squibb, Analysis Group, Eli Lilly Taiwan, Kantar Health, Merck Serono, Pharmerit Asia Pacific, Quintiles, Takeda Pharmaceuticals Taiwan, Truven Health Analytics and ZRx Outcomes Research

Exhibit

Present your products and services to key outcomes researchers and health care decision-makers in pharmaceutical, medical device and diagnostics, biotechnology, clinical practice, government agencies, academia, and health care organizations. For more information, please e-mail: exhibit@ispor.org

Exhibitors from the 2014 Conference included:

Amaris, Analysis Group, Azmi Burhani Consulting, Costello Medical Singapore, Creativ-Ceutical, CRECON Research and Consulting, ESSEC Business School, Health Economics and Health Technology Assessment Research Group, University of Glasgow, HTA Consulting, ICON, IMS Health, Ipsos Healthcare, Japan Medical Data Center, Kantar Health, Optum, Pharmerit Asia Pacific, Quintiles, RR Donnelley Language Solutions, TransPerfect, Truven Health Analytics, Wonder Drug Consulting and ZRx Outcomes Research

Visit ISPOR Asia Consortium at <http://www.ispor.org/consortiums/asia.asp>



1260 delegates from 53 countries participated at the ISPOR 6th Asia-Pacific Conference, Beijing, China in 2014.

Corporate Sponsorship

ISPOR offers opportunities for organizations to financially support the ISPOR 7th Asia-Pacific Conference. For more information, please e-mail: asiaconsortium@ispor.org

Educational Symposia

Only 3 symposia opportunities remain!

Educational Symposia are sponsored presentations that are open to all conference delegates. For more information, please e-mail: asiaconsortium@ispor.org

Educational Forums

Educational Forums are sponsored educational meetings held during ISPOR Asia-Pacific Conferences (formerly Asia Educational Roundtables) For more information, please e-mail: asiaconsortium@ispor.org

WELCOME RECEPTION

Welcome Reception for all conference delegates features traditional cultural performances and provides a great opportunity to meet key opinion leaders from Asia-Pacific region and from countries around the world.



Welcome Reception at the ISPOR 6th Asia-Pacific Conference in Beijing, China in 2014

Visit the ISPOR 7th Asia-Pacific Conference Website for information and registration: <http://www.ispor.org/Event/Index/2016Singapore>